Crossmark

Development and evaluating multimarker models for guiding treatment decisions

Crossref DOI link: https://doi.org/10.1186/s12911-018-0619-5

Published Online: 2018-06-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tajik, Parvin http://orcid.org/0000-0003-3945-853X
Zafarmand, Mohammad Hadi

Zwinderman, Aeilko H.

Mol, Ben W.

Bossuyt, Patrick M.
Funding

Funding for this research was provided by:

ZonMw (200310004)

AXA Research Fund
License Information

Text and Data Mining valid from 2018-06-28
More Information

Article History

Received: 17 March 2017

Accepted: 30 May 2018

First Online: 28 June 2018

Ethics approval and consent to participate

: The data for this analysis were collected in the ProTwin trial (NTR1858), reported in detail elsewhere data.The ProTwin trial received ethics approval from the Medical Ethics Committee of the Academic Medical Centre of the University of Amsterdam, The Netherlands (MEC O9/1O7), and received approval for local execution, in line with the Dutch legal requirements for research in humans, from all other participant center. All participants provided written informed consent prior to study entry and were aware that the data they contributed were used to analyze the effect of a pessary on pregnancy outcome in multiple pregnancies. The full names and affiliations of the AMC ethics committee are provided in the “AMC Medical Ethics Committee Approval_ProTWIN” letter which can be accessed at the trial website.

: We declare that we have no competing interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.